HK1042493A1 - 新的化合物 - Google Patents
新的化合物 Download PDFInfo
- Publication number
- HK1042493A1 HK1042493A1 HK02104304.1A HK02104304A HK1042493A1 HK 1042493 A1 HK1042493 A1 HK 1042493A1 HK 02104304 A HK02104304 A HK 02104304A HK 1042493 A1 HK1042493 A1 HK 1042493A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- solvates
- pharmaceutically acceptable
- new compounds
- carboxypeptidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901572-9 | 1999-05-03 | ||
| SE9901572A SE9901572D0 (sv) | 1999-05-03 | 1999-05-03 | New compounds |
| PCT/SE2000/000846 WO2000066550A1 (en) | 1999-05-03 | 2000-05-03 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1042493A1 true HK1042493A1 (zh) | 2002-08-16 |
Family
ID=20415425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK02104304.1A HK1042493A1 (zh) | 1999-05-03 | 2000-05-03 | 新的化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7354895B1 (https=) |
| EP (1) | EP1180099A1 (https=) |
| JP (1) | JP4270759B2 (https=) |
| KR (1) | KR20020010631A (https=) |
| CN (1) | CN1358187A (https=) |
| AR (1) | AR028826A1 (https=) |
| AU (1) | AU4447100A (https=) |
| BR (1) | BR0010256A (https=) |
| CA (1) | CA2371215A1 (https=) |
| CZ (1) | CZ20013931A3 (https=) |
| EE (1) | EE200100573A (https=) |
| HK (1) | HK1042493A1 (https=) |
| HU (1) | HUP0202379A3 (https=) |
| IL (1) | IL145953A0 (https=) |
| IS (1) | IS6141A (https=) |
| MX (1) | MXPA01011043A (https=) |
| NO (1) | NO20015374D0 (https=) |
| PL (1) | PL356140A1 (https=) |
| SE (1) | SE9901572D0 (https=) |
| SK (1) | SK15662001A3 (https=) |
| TR (1) | TR200103144T2 (https=) |
| WO (1) | WO2000066550A1 (https=) |
| ZA (2) | ZA200108966B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100681632B1 (ko) * | 1999-09-14 | 2007-02-09 | 메이지 세이카 가이샤 리미티드 | 카르복시펩티다아제 ｂ 저해활성을 갖는 포스폰산 유도체 |
| PL361054A1 (en) * | 2000-08-17 | 2004-09-20 | Pfizer Inc. | Substituted imidazoles as tafia inhibitors |
| SE0103272D0 (sv) | 2001-09-28 | 2001-09-28 | Astrazeneca Ab | Chemical compounds |
| WO2003061653A1 (en) | 2002-01-22 | 2003-07-31 | Pfizer Limited | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| US6713496B2 (en) | 2002-01-22 | 2004-03-30 | Pfizer Inc | 3-(imidazolyl)-2-alkoxypropanoic acids |
| EP1467731A1 (en) * | 2002-01-22 | 2004-10-20 | Pfizer Limited | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| EP1497300A2 (en) * | 2002-03-21 | 2005-01-19 | Schering Aktiengesellschaft | Plasma carboxypeptidase b inhibitors |
| NZ592764A (en) | 2008-10-29 | 2012-08-31 | Taisho Pharmaceutical Co Ltd | Compound having tafia inhibitory activity |
| CN113395996B (zh) | 2019-02-08 | 2024-05-28 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| CN111110837B (zh) * | 2020-01-06 | 2022-11-25 | 中国人民解放军陆军军医大学 | 一种羧肽酶抑制剂在制备预防重症致死性轮状病毒感染药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2516307A (en) * | 1949-01-06 | 1950-07-25 | Gen Mills Inc | Vinyl resins plasticized with cyano esters |
| US4560680A (en) * | 1982-03-15 | 1985-12-24 | E. R. Squibb & Sons, Inc. | Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors |
| US4849414A (en) * | 1986-06-11 | 1989-07-18 | E. R. Squibb & Sons, Inc. | Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors |
| FR2610951B1 (fr) * | 1987-02-17 | 1989-05-05 | Aerospatiale | Armature tissee pour materiau composite |
| IL86951A (en) * | 1987-07-06 | 1996-07-23 | Procter & Gamble Pharma | Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them |
| JPH07502507A (ja) * | 1991-12-17 | 1995-03-16 | プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド | ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法 |
| US5550119A (en) * | 1995-03-02 | 1996-08-27 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives as ECE inhibitors |
| US5672592A (en) * | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| JP3440305B2 (ja) * | 1997-04-02 | 2003-08-25 | 高砂香料工業株式会社 | ７−（ｎ−置換アミノ）−２−フェニルヘプタン酸 エステル誘導体及び該誘導体の製造方法 |
| PT973512E (pt) | 1997-02-27 | 2004-07-30 | Wyeth Corp | N-hidroxi-2-(alquil, aril ou heteroaril sulfanil, sulfinilou sulfonil)-alquil, aril ou heteroarilamidas substituidas na posicao 3 como inibidores de metaloproteinases da matriz |
| AR023819A1 (es) * | 1999-05-03 | 2002-09-04 | Astrazeneca Ab | FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION |
| SE9901573D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| KR100681632B1 (ko) * | 1999-09-14 | 2007-02-09 | 메이지 세이카 가이샤 리미티드 | 카르복시펩티다아제 ｂ 저해활성을 갖는 포스폰산 유도체 |
-
1999
- 1999-05-03 SE SE9901572A patent/SE9901572D0/xx unknown
-
2000
- 2000-04-28 AR ARP000102082A patent/AR028826A1/es not_active Application Discontinuation
- 2000-05-03 CZ CZ20013931A patent/CZ20013931A3/cs unknown
- 2000-05-03 WO PCT/SE2000/000846 patent/WO2000066550A1/en not_active Ceased
- 2000-05-03 KR KR1020017014014A patent/KR20020010631A/ko not_active Withdrawn
- 2000-05-03 JP JP2000615381A patent/JP4270759B2/ja not_active Expired - Fee Related
- 2000-05-03 PL PL00356140A patent/PL356140A1/xx not_active Application Discontinuation
- 2000-05-03 MX MXPA01011043A patent/MXPA01011043A/es unknown
- 2000-05-03 EP EP00925844A patent/EP1180099A1/en not_active Ceased
- 2000-05-03 AU AU44471/00A patent/AU4447100A/en not_active Abandoned
- 2000-05-03 HU HU0202379A patent/HUP0202379A3/hu unknown
- 2000-05-03 CA CA002371215A patent/CA2371215A1/en not_active Abandoned
- 2000-05-03 TR TR2001/03144T patent/TR200103144T2/xx unknown
- 2000-05-03 EE EEP200100573A patent/EE200100573A/xx unknown
- 2000-05-03 SK SK1566-2001A patent/SK15662001A3/sk unknown
- 2000-05-03 IL IL14595300A patent/IL145953A0/xx unknown
- 2000-05-03 CN CN00809484A patent/CN1358187A/zh active Pending
- 2000-05-03 US US09/600,660 patent/US7354895B1/en not_active Expired - Fee Related
- 2000-05-03 BR BR0010256-3A patent/BR0010256A/pt not_active Application Discontinuation
- 2000-05-03 HK HK02104304.1A patent/HK1042493A1/zh unknown
-
2001
- 2001-10-30 ZA ZA200108966A patent/ZA200108966B/en unknown
- 2001-10-30 ZA ZA200108967A patent/ZA200108967B/en unknown
- 2001-11-01 IS IS6141A patent/IS6141A/is unknown
- 2001-11-02 NO NO20015374A patent/NO20015374D0/no not_active Application Discontinuation
-
2005
- 2005-12-02 US US11/293,060 patent/US7423012B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002543179A (ja) | 2002-12-17 |
| MXPA01011043A (es) | 2002-06-04 |
| JP4270759B2 (ja) | 2009-06-03 |
| CA2371215A1 (en) | 2000-11-09 |
| SE9901572D0 (sv) | 1999-05-03 |
| EE200100573A (et) | 2003-02-17 |
| AR028826A1 (es) | 2003-05-28 |
| SK15662001A3 (sk) | 2002-09-10 |
| ZA200108967B (en) | 2003-01-30 |
| CN1358187A (zh) | 2002-07-10 |
| US7354895B1 (en) | 2008-04-08 |
| NO20015374L (no) | 2001-11-02 |
| WO2000066550A8 (en) | 2001-01-25 |
| ZA200108966B (en) | 2003-01-30 |
| TR200103144T2 (tr) | 2004-11-22 |
| EP1180099A1 (en) | 2002-02-20 |
| KR20020010631A (ko) | 2002-02-04 |
| WO2000066550A1 (en) | 2000-11-09 |
| HUP0202379A3 (en) | 2003-04-28 |
| IL145953A0 (en) | 2002-11-10 |
| IS6141A (is) | 2001-11-01 |
| HUP0202379A2 (hu) | 2002-12-28 |
| BR0010256A (pt) | 2002-02-13 |
| AU4447100A (en) | 2000-11-17 |
| US20060079484A1 (en) | 2006-04-13 |
| CZ20013931A3 (cs) | 2002-04-17 |
| PL356140A1 (en) | 2004-06-14 |
| NO20015374D0 (no) | 2001-11-02 |
| US7423012B2 (en) | 2008-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1042303A1 (zh) | 新的化合物 | |
| CA2105180A1 (en) | Compositions containing sumatriptan | |
| AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
| CA2427227A1 (en) | Lactam compound | |
| GEP20053673B (en) | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | |
| AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
| WO2004052847A3 (en) | Tricyclic steroid hormone nuclear receptor modulators | |
| WO2004108162A3 (en) | Controlled release pharmaceutical composition | |
| WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| GB0109122D0 (en) | Novel compounds | |
| DK0920865T3 (da) | Farmaceutiske sammensætninger indeholdende norastemizol | |
| EP0220523A3 (en) | Novel quinolinecarboxylic acid compounds, processes for preparing them, pharmaceutical composition and use | |
| WO2002000166A3 (en) | New compounds useful as antibacterial agents | |
| HK1042493A1 (zh) | 新的化合物 | |
| MY160429A (en) | 2, 5-disubstituted 3-mercaptopentanoic acid | |
| HU9802897D0 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient | |
| WO1999045909A3 (en) | Use of nitrone compounds for the inhibition of angiogenesis | |
| CA2373962A1 (en) | Immediate release medicinal compositions for oral use | |
| BE2016C017I2 (https=) | ||
| MY133438A (en) | Morpholinobenzamide salts | |
| DE60233578D1 (de) | Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung | |
| CA2370501A1 (en) | Pharmaceutical composition for the therapy of lower urinary tract symptoms | |
| CA2409845A1 (en) | Active substance combination containing a compound with an opioid effect and at least one further compound of formula i | |
| TW200509915A (en) | Novel oxazoles, their manufacture and use as pharmaceutical agents | |
| EP1685837A4 (en) | BRAIN PROTECTIVE AGENT OF THE TYPE ADMINISTERED BY PERCUTANEOUS ABSORPTION |